Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome
Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome
复制标题
DOI：
10.1046/j.1538-7836.2003.00147.x
复制
发表时间：
2003-04-01
影响因子：
10.4
通讯作者：
Alessi, MC
中科院分区：
文献类型：
--
作者：
Aubert, H;Frère, C;Alessi, MC
血浆凝血酶激活的纤维蛋白溶解抑制物（TAFI）水平的增加最近被证明是胰岛素抵抗综合征的一部分。我们研究了血浆TAR抗原水平和胰岛素抵抗标志物之间的关系，并将这些结果与已知分别与胰岛素抵抗综合征和脂肪量密切相关的派-1和纤维蛋白原的结果进行了比较。89名肥胖女性的循环TAFI分别高出1.3倍、1.2倍和3倍。纤维蛋白原和派-1，分别与64瘦女性相比。单因素分析显示，TAFI或纤维蛋白原浓度与胰岛素抵抗标志物之间的关联的显著性水平低于派-1与胰岛素抵抗标志物之间的关联的显著性水平。尽管如此。TAR纤维蛋白原和派-1血浆水平彼此显著相关。在线性逐步上升分析中，胰岛素抵抗标志物占血浆派-1个体间变异的50%，仅占血浆TAFI的10%和纤维蛋白原变异的13%。当派-1或纤维蛋白原进入统计模型时，胰岛素抵抗标志物对血浆TAFI抗原水平变异性的贡献消失。TAR mRNA在肝脏中检测到，但在脂肪组织和内皮细胞中未检测到。在正常血管和动脉粥样硬化血管中均未检测到TAFI mRNA。这些结果表明，肥胖受试者中发现的TAR抗原水平升高与胰岛素抵抗综合征的代谢标志物并不独立相关。肥胖患者血浆TAFI抗原水平升高可能反映了肝脏水平的特定调节途径。
Increased plasma thrombin-activatable fibrinolysis inhibitor (TAFI) levels were recently shown to be a part of the insulin resistance syndrome. We investigated the relationship between plasma TAR antigen levels and insulin resistance markers and compared these results with those obtained for PAI-1 and fibrinogen which are known to be closely related to insulin resistance syndrome and fat mass, respectively. Eighty-nine obese females had 1.3-, 1.2-, and 3-fold higher circulating TAFI. fibrinogen and PAI-1, respectively, compared with 64 lean females. Univariate analysis showed that the significance level for association between TAFI or fibrinogen concentrations and insulin resistance markers was lower than the significance level for association between PAI-1 and insulin resistance markers. Nevertheless. TAR fibrinogen, and PAI-1 plasma levels were significantly associated to each other. In linear stepwise ascendant analysis, insulin resistance markers accounted for 50% of the interindividual variability of plasma PAI-1 and only for 10% of plasma TAFI and 13% of fibrinogen variability. The contribution of insulin resistance markers to plasma TAFI antigen levels variability disappeared when PAI-1 or fibrinogen was entered in the statistical model. TAR mRNA was detected in the liver but not in adipose tissue and endothelial cells. No TAFI mRNA was detected in normal or atherosclerotic vessels either. These results suggest that elevated TAR antigen levels found in obese subjects are not independently associated with the metabolic markers of the insulin resistance syndrome. Increased plasma TAFI antigen levels in obesity might reflect a specific pathway of regulation at the liver level.